Amgen and Servier have inched closer to a verdict on their first-in-class chronic heart failure drug omecamtiv mecarbil, after their first phase 3 study passed a futility review.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,